Ketorolac Eye Drops Manufacturer in India

Ketorolac 0.4% ophthalmic NSAID eye drops are indicated for: relief of ocular itching due to seasonal allergic conjunctivitis, post-operative pain and inflammation following cataract extraction, prevention of intraoperative miosis (pupil constriction) during surgery, and reduction of cystoid macular oedema (CMO) risk post-cataract surgery. They are increasingly used alongside or instead of corticosteroid eye drops where steroid side effects are a concern.

NSAID eye drops like Ketorolac carry no risk of steroid-induced intraocular pressure elevation, posterior subcapsular cataract formation or increased susceptibility to infection — side effects associated with prolonged corticosteroid use. Ketorolac is preferred for longer-term anti-inflammatory use, in patients with glaucoma or steroid responders, and for prevention of CMO post-cataract surgery where a prolonged anti-inflammatory course is beneficial.

Yes. Ketorolac 0.4% eye drops are widely used in the peri-operative management of cataract surgery: pre-operatively (3 doses in the hour before surgery) to prevent intraoperative miosis and reduce prostaglandin-mediated pupil constriction, intraoperatively as supplemental irrigating solution in some protocols, and post-operatively for 2–4 weeks to prevent CMO and manage post-surgical pain and inflammation.

Yes. Combined use of a corticosteroid eye drop (Prednisolone) and an NSAID eye drop (Ketorolac) post- cataract surgery is the standard dual anti-inflammatory protocol in most ophthalmic surgery centres globally. The two agents work through different anti-inflammatory pathways and their combination provides more complete inflammation control with a lower steroid dose requirement — reducing steroid side effect risk.

Ketorolac 0.4% ophthalmic solution is available in 5ml sterile multi-dose bottles. Institutional packaging for hospital surgical programmes and custom private label export packaging are available. Please contact our export team for volume-specific pricing and packaging requirements.

Documentation available includes WHO-GMP Certificate, DCGI Manufacturing Licence, CoPP, batch- wise CoA (sterility, particulate matter, pH, assay), ICH Zone IVb stability data and CTD/ACTD dossiers on request. Ketorolac eye drops are part of 9M India's active ophthalmic export portfolio for the Middle East, CIS, Africa and ASEAN markets.

Ketorolac ophthalmic NSAID demand is highest in markets with high cataract surgery volume — which includes all of 9M India's Phase 1 export markets. Cataract blindness burden is highest in South Asia, Africa and the Middle East, driving large-scale cataract surgical programmes in which Ketorolac is a standard peri-operative component. Institutional and government programme supply represents the primary demand channel.